Published in Nature on February 19, 2014
Immune cell promotion of metastasis. Nat Rev Immunol (2015) 2.15
Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature (2016) 2.11
Metastatic colonization by circulating tumour cells. Nature (2016) 1.31
TAM receptor signaling in immune homeostasis. Annu Rev Immunol (2015) 1.18
Inhibition of CBLB protects from lethal Candida albicans sepsis. Nat Med (2016) 1.17
AXL kinase as a novel target for cancer therapy. Oncotarget (2014) 1.14
Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol (2016) 1.12
Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 1.06
Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J Biol Chem (2014) 1.05
The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity. Nat Med (2015) 1.02
A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst (2014) 1.02
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ (2016) 1.01
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clin Cancer Res (2016) 1.00
Axl as a mediator of cellular growth and survival. Oncotarget (2014) 0.99
Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. Lab Invest (2015) 0.98
Orchestration of angiogenesis by immune cells. Front Oncol (2014) 0.97
An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat Chem Biol (2014) 0.96
The new deal: a potential role for secreted vesicles in innate immunity and tumor progression. Front Immunol (2015) 0.93
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol (2016) 0.91
Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment. Clin Cancer Res (2014) 0.90
The AXL Receptor is a Sensor of Ligand Spatial Heterogeneity. Cell Syst (2015) 0.88
Inhibition of reactive oxygen species production ameliorates inflammation induced by influenza A viruses via upregulation of SOCS1 and SOCS3. J Virol (2014) 0.87
E3 ubiquitin ligase Cbl-b in innate and adaptive immunity. Cell Cycle (2014) 0.86
Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Cancer Res (2015) 0.86
Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy (2014) 0.85
The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate. Cell Rep (2016) 0.84
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches. Front Immunol (2016) 0.84
Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy. Oncotarget (2015) 0.83
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Cancer Biol Ther (2014) 0.81
A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Dis Model Mech (2015) 0.81
Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. Front Oncol (2015) 0.81
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther (2016) 0.80
TAM Receptors Are Not Required for Zika Virus Infection in Mice. Cell Rep (2017) 0.79
Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Cell Commun Signal (2016) 0.79
MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. Oncotarget (2016) 0.78
Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis. Chin J Cancer (2017) 0.78
Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. J Thorac Oncol (2016) 0.78
NEDD4: a promising target for cancer therapy. Curr Cancer Drug Targets (2014) 0.78
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo. Oncotarget (2016) 0.78
Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer (2017) 0.77
A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6. Cancer Sci (2016) 0.77
TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev (2017) 0.77
Microfluidics: A new tool for modeling cancer-immune interactions. Trends Cancer (2016) 0.76
A novel CBL-Bflox/flox mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells. Oncotarget (2016) 0.76
E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity. J Exp Med (2016) 0.76
Mouse genomic screen reveals novel host regulator of metastasis. Genome Biol (2017) 0.75
Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med (2017) 0.75
Immunotherapy: killing with natural killers, naturally. Nat Rev Clin Oncol (2014) 0.75
Cbl-b: Roles in T Cell Tolerance, Proallergic T Cell Development, and Cancer Immunity. Inflamm Cell Signal (2015) 0.75
Cancer: Unleashing NK cell anti-metastatic activity. Nat Rev Drug Discov (2014) 0.75
Targeting the TAM Receptors in Leukemia. Cancers (Basel) (2016) 0.75
Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response. Cancers (Basel) (2016) 0.75
Signalling: loss of Cbl-b unleashes anti-metastatic natural killer cells. Nat Rev Cancer (2014) 0.75
TAM receptor tyrosine kinase function and the immunopathology of liver disease. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Cbl-b Deficiency in Mice Results in Exacerbation of Acute and Chronic Stages of Allergic Asthma. Front Immunol (2015) 0.75
The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy. Cancers (Basel) (2016) 0.75
Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells. FASEB J (2016) 0.75
Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Sci Rep (2017) 0.75
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. Clin Cancer Res (2016) 0.75
Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation. Front Immunol (2017) 0.75
Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling. Oncotarget (2016) 0.75
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Curr Oncol Rep (2017) 0.75
The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle (2017) 0.75
The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers (Basel) (2016) 0.75
Immune Regulation of the Metastatic Process: Implications for Therapy. Adv Cancer Res (2016) 0.75
Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun (2016) 0.75
Type I Interferons and Natural Killer Cell Regulation in Cancer. Front Immunol (2017) 0.75
The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nat Commun (2017) 0.75
Axl signaling induces development of natural killer cells in vitro and in vivo. Protoplasma (2016) 0.75
Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma. Oncotarget (2017) 0.75
Tumor cell dormancy. Mol Oncol (2016) 0.75
Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition. Oncotarget (2017) 0.75
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science (2001) 4.42
Immunobiology of the TAM receptors. Nat Rev Immunol (2008) 4.26
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08
The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity (2002) 3.85
TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res (2008) 3.63
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A (2007) 3.60
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A (2001) 3.21
Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem (1996) 2.77
An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A (2003) 2.75
Mouse 4T1 breast tumor model. Curr Protoc Immunol (2001) 2.46
Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat Immunol (2006) 2.15
Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int Immunol (1995) 2.02
Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic (2009) 1.83
The role of ubiquitylation in receptor endocytosis and endosomal sorting. J Cell Sci (2012) 1.73
In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature (1981) 1.71
Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol (2006) 1.50
In vivo depletion of natural killer cell activity leads to enhanced multiplication of Mycobacterium avium complex in mice. Infect Immun (1991) 1.47
Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1. Proc Natl Acad Sci U S A (2009) 1.34
Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem (2003) 1.32
A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases. Cancer Res (1973) 1.32
Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest (2007) 1.29
Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cells. J Immunol (2006) 1.28
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28
Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide. J Immunol Methods (2001) 1.22
Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions. J Immunol (2011) 1.18
Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis. Am J Pathol (2001) 1.17
Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol (2008) 1.15
The role of gamma-carboxylation in the anti-apoptotic function of gas6. J Thromb Haemost (2005) 1.14
Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics (2004) 1.12
Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. Biochem Biophys Res Commun (2005) 0.99
Roadblocks to translational advances on metastasis research. Nat Med (2013) 0.98
The Cbl-b RING finger domain has a limited role in regulating inflammatory cytokine production by IgE-activated mast cells. Mol Immunol (2007) 0.97
Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth. Br J Cancer (1989) 0.90
Immunobiology of her-2/neu transgenic mice. Breast Dis (2004) 0.89
Reduced incidence of spontaneous metastases with long-term Coumadin therapy. Ann Surg (1968) 0.82
[Effect of dicoumarol on the development of metastases of the T8 epithelioma in the rat; new research]. Bull Assoc Fr Etud Cancer (1958) 0.75
RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1. Stem Cell Reports (2015) 0.88
KCNJ15/Kir4.2 couples with polyamines to sense weak extracellular electric fields in galvanotaxis. Nat Commun (2015) 0.85
Identification of pyrazolopyridazinones as PDEδ inhibitors. Nat Commun (2016) 0.79